Del Mar

Researchers are evaluating the effects of a health and wellness product on gastrointestinal health and related health outcomes in adults aged 21 to 75. The study aims to understand participant experiences using the product, its side effects, how participants accept and use it, and its impact on health through self-reported surveys and biomarker collections. The focus includes users of GLP-1 medications and those interested in losing weight but not currently using GLP-1. Participants will consume a ready-to-mix beverage containing protein, fiber, and electrolytes freely over a 4-week period. The study is open-label and direct-to-consumer, with participants taking the product daily and providing biomarker samples at the start and end of the study. During the study, participants will complete electronic surveys and provide stool and blood samples at two timepoints to assess changes. Researchers will monitor the quality of life and gastrointestinal health using self-reported measures, including the PROMIS Constipation 9A assessment at baseline and weekly for four weeks. The total participation duration is four weeks with ongoing safety and health outcome monitoring throughout this period.

Researchers are evaluating whether the HAPPI software can improve how pharmacists provide birth control services and how patients access these services. The study aims to find out if the software makes it easier for pharmacists to deliver birth control and for patients to receive it. This trial involves pharmacists and patients in community pharmacies, focusing on contraception and healthcare access using technology. Fifteen community pharmacies will first provide birth control services as usual for several months without the software (control period). Then, these pharmacies will switch to using the HAPPI software instead of their previous paper or electronic processes to provide birth control services (intervention period). The results from the two periods will be compared to see if the software improves service implementation and patient access. Participants will include pharmacists providing birth control services and patients seeking these services at the participating pharmacies. Researchers will measure factors like the number of pharmacists and pharmacy staff involved, how payments are made (cash or insurance billing), and other implementation outcomes within five months. The study will monitor how well the software integrates into pharmacy services and its impact on birth control access over the study period.

Researchers are evaluating the impact of health and wellness products on mental clarity and related health outcomes in adults aged 35 to 60 living in the United States. This randomized, double-blind, placebo-controlled study focuses on participants who have the potential for meaningful improvement in cognitive function and are willing to take a study product without knowing its identity until the study ends. Participants with certain medical conditions, heavy alcohol use, pregnancy, or medication contraindications may be excluded. Participants are randomly assigned to use either the RS Clarity Active Product or a placebo version, both dietary supplements, as directed for 12 weeks. The study is conducted entirely remotely, with no in-person visits. All data collection, including health reports and assessments, is done electronically throughout the 12-week product usage period. During the study, participants provide self-reported data on health indicators at enrollment and regularly during the 12 weeks. Researchers monitor changes in cognitive function as the primary outcome after 13 weeks. The study tracks safety and health outcomes through electronic questionnaires and reports, ensuring participant privacy and convenience in this direct-to-consumer research.

Researchers are evaluating the impact of health and wellness products on cognitive function and related health outcomes in adults living in the United States. This randomized, double-blind, placebo-controlled study is designed to assess meaningful improvement of at least 30% in participants' primary health outcome over 13 weeks. The study excludes individuals with certain medical conditions, safety concerns, or contraindications to the products being tested. Participants will be randomly assigned to use either an active dietary supplement containing Himalayan Tartary buckwheat, a high-polyphenol non-grain fruit seed, or a placebo control product. Both products are taken as directed for 12 weeks. Participants will not know which product they are receiving until the study ends, maintaining the double-blind design. Throughout the 13-week study, participants will provide self-reported health data electronically, including baseline information and reports during product use and at a final survey. No in-person visits or assessments are required, and all data collection is done remotely. The primary outcome measured is change in cognitive function after 13 weeks of product use, with continuous monitoring of safety and adherence via electronic reporting.

Researchers are evaluating the effects of health and wellness products on gastrointestinal (GI) health and related outcomes in adults living in the United States. This randomized, double-blind, placebo-controlled study includes participants who may experience at least a 30% improvement in their primary health outcome, which focuses on changes in belly pain over 7 weeks. Participants agree to take a study product without knowing if it is active or a placebo until the study ends. Participants will use one of three dietary supplements—either a placebo control or one of two active GI health products—as directed for 6 weeks. The study collects self-reported data electronically with no in-person visits or assessments. Health indicators are recorded at enrollment and throughout the active product use period to monitor changes and effects. During the study, participants will provide electronic reports of their health status and symptoms over 6 weeks. Researchers will measure the change in belly pain and other related health outcomes. There is no physical clinic visit; all assessments and data collection are done remotely. Safety is monitored by excluding participants with certain medical conditions or medication use that could pose risks with the study products.

Researchers are evaluating the impact of health and wellness products on health issues related to menopause, focusing on cognitive function. This randomized, double-blind, placebo-controlled study involves adult women in the United States who are peri- or post-menopausal and regularly experience hot flashes. The study excludes those taking hormone replacement therapy or with certain health conditions or medication interactions that pose safety risks. Participants will be assigned to use either an active product or a placebo control product, both dietary supplements, as directed for 12 weeks. The study is conducted entirely electronically, with no in-person visits, allowing participants to take the products at home while reporting their health indicators throughout the study period. Participants will provide self-reported data electronically for 13 weeks, including at enrollment and during product use. The main outcome measured is the change in cognitive function after 13 weeks. Researchers will monitor safety and health outcomes through electronic assessments and participant reports, with the entire study focused on real-world evidence collection.